Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.30M | -15.77M | -12.27M | -17.93M | -19.79M |
| Total Depreciation and Amortization | -- | 1.00K | 1.00K | 1.00K | 14.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.13M | 5.00M | 206.00K | 1.76M | 686.00K |
| Change in Net Operating Assets | -404.00K | 1.12M | 3.04M | 5.51M | 6.54M |
| Cash from Operations | -10.57M | -9.65M | -9.02M | -10.66M | -12.55M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 382.00K | 382.00K | 382.00K | 382.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 382.00K | 382.00K | 382.00K | 382.00K |
| Total Debt Issued | 2.10M | 2.10M | 0.00 | 1.00M | 1.00M |
| Total Debt Repaid | -1.05M | -1.90M | -2.04M | -2.15M | -1.86M |
| Issuance of Common Stock | 10.76M | 9.04M | 9.04M | 12.87M | 11.95M |
| Repurchase of Common Stock | -- | -- | -107.00K | -107.00K | -107.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.37M | 330.00K | 330.00K | -- | -- |
| Cash from Financing | 13.17M | 9.57M | 7.23M | 11.61M | 10.99M |
| Foreign Exchange rate Adjustments | 1.00K | 2.00K | 7.00K | 1.00K | -4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.60M | 298.00K | -1.41M | 1.33M | -1.19M |